Anchored in the Research organization at LEO Pharma, Camilla's team is responsible for driving key deliveries to LEO´s 2025 strategy that targets development of intervention against some of this World’s most painful and life-threatening genetic and autoimmune diseases for which no treatment or cure currently exist.
To that end, she established the Patient Engagement function at LEO, implying a responsibility for the strategic and operational patient engagement activities. This is to ensure that all key decisions are informed by patient KOLs and communities, as well as executed in partnership with the mentioned.
Prior to joining LEO in May 2018, Camilla established and led the Patient Engagement function at Abbott, AbbVie and Novo Nordisk. Prior to joining pharma, she worked for science/patient alliances and for patient organizations.
In her view, ‘Patients’ are indeed disease experience experts, and at LEO this translate into a ‘Nothing About You Without You’ mantra and commitment that shape our approach and daily strive to develop solution for people affected by rare disease with severe skin manifestations.
In terms of academic training, She holds Master degrees in Molecular Biology, Corporate Communication and Business Administration.
More speakers Announced soon
Please check back later for updates.
We are proud to announce that EPF Congress 2019 is Patients Included™. This means that EPF is committed to incorporating the experience of patients as experts in living with their condition while ensuring they were neither excluded nor exploited.More information
The website you’re trying to visit is from the 2019 edition of the EPF Congress. To get informations for this year’s event please follow the right link below.